was an essential element in the development and conduct of the ERSPC and PRIAS trials. It is very satisfying to be aware that important unresolved questions concerning the early diagnosis and management of prostate cancer can still be addressed by results derived from our trials. This will hopefully result in a level of understanding of the advantages and disadvantages of screening for prostate cancer which will lead to the worldwide reduction of the incidence and mortality of this disease at an acceptable rate of side effects. In many countries prostate cancer is the second or third most frequent cause of death from cancer in males.
